INTERCEPT PHARMACEUTICALS, INC. (NASDAQ:ICPT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the 2017 annual meeting of stockholders of Intercept
Pharmaceuticals, Inc. (the Company) held on June 27, 2017, the
Companys stockholders (1) elected all nine nominees to serve on
the Companys board of directors, (2) approved, on a non-binding
advisory basis, the compensation of our named executive officers,
and (3) ratified the appointment of KPMG LLP as the Companys
independent registered public accounting firm for the fiscal year
ending December 31, 2017. Shares of the Companys voting stock
were voted on these proposals as follows:
Proposal 1. Election of Directors: Nine nominees were
elected to serve on the Companys board of directors until the
next annual meeting of stockholders and until their successors
are elected and qualified with the votes set forth below:
| Name | For | Withheld | Broker Non-Votes |
| Srinivas Akkaraju | 19,672,615 | 17,439 | 1,714,966 |
| Luca Benatti | 19,673,119 | 16,935 | 1,714,966 |
| Daniel Bradbury | 19,535,777 | 154,277 | 1,714,966 |
| Paolo Fundaro | 19,639,210 | 50,844 | 1,714,966 |
| Keith Gottesdiener | 19,677,222 | 12,832 | 1,714,966 |
| Mark Pruzanski | 19,685,142 | 4,912 | 1,714,966 |
| Gino Santini | 19,533,040 | 157,014 | 1,714,966 |
| Glenn Sblendorio | 19,670,833 | 19,221 | 1,714,966 |
| Daniel Welch | 19,232,475 | 457,579 | 1,714,966 |
Proposal 2. Advisory Vote on Executive
Compensation.The stockholders approved, on a
non-binding advisory basis, the executive compensation of the
Companys named executive officers as described in the Proxy
Statement. The final voting results with respect to this Proposal
were as follows: 19,553,184 votes for; 122,985 votes against;
13,885 votes abstaining; and 1,714,966 broker non-votes.
Proposal 3. Ratification of Independent Registered Public
Accounting Firm: The stockholders ratified the appointment of
KPMG LLP as the Companys independent registered public accounting
firm for the fiscal year ending December 31, 2017. The final
voting results with respect to this Proposal were as follows:
21,297,874 votes for; 80,207 votes against; and 26,939 votes
abstaining.
About INTERCEPT PHARMACEUTICALS, INC. (NASDAQ:ICPT)
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is developing OCA for the treatment of liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic steatoheptitis (NASH), primary sclerosing cholangitis (PCS) and biliary atresia. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.